Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Nov 27 04:00PM ET
1.00
Dollar change
+0.00
Percentage change
0.16
%
Index- P/E- EPS (ttm)-1.13 Insider Own64.77% Shs Outstand42.33M Perf Week0.00%
Market Cap59.44M Forward P/E- EPS next Y-0.62 Insider Trans0.00% Shs Float20.91M Perf Month1.57%
Income-52.31M PEG- EPS next Q-0.18 Inst Own4.18% Short Float1.40% Perf Quarter25.34%
Sales4.19M P/S14.18 EPS this Y84.66% Inst Trans21.65% Short Ratio0.92 Perf Half Y10.27%
Book/sh-0.96 P/B- EPS next Y29.51% ROA-160.52% Short Interest0.29M Perf Year-28.57%
Cash/sh0.24 P/C4.10 EPS next 5Y- ROE-1007.83% 52W Range0.63 - 1.58 Perf YTD-29.08%
Dividend Est.- P/FCF- EPS past 5Y-110.66% ROI-626.59% 52W High-36.71% Beta1.42
Dividend TTM- Quick Ratio1.11 Sales past 5Y103.89% Gross Margin-90.62% 52W Low58.70% ATR (14)0.06
Dividend Ex-Date- Current Ratio1.18 EPS Y/Y TTM19.59% Oper. Margin-1077.37% RSI (14)57.16 Volatility5.34% 6.95%
Employees70 Debt/Eq2.06 Sales Y/Y TTM179.27% Profit Margin-1248.84% Recom1.00 Target Price3.54
Option/ShortNo / Yes LT Debt/Eq0.32 EPS Q/Q27.64% Payout- Rel Volume0.91 Prev Close1.00
Sales Surprise3.12% EPS Surprise2.91% Sales Q/Q49.68% EarningsNov 13 BMO Avg Volume319.41K Price1.00
SMA201.34% SMA5011.90% SMA20010.41% Trades Volume292,168 Change0.16%
Date Action Analyst Rating Change Price Target Change
Dec-27-21Initiated Ascendiant Capital Markets Buy $16
Nov-08-21Initiated Needham Buy $17
Nov-08-21Initiated Cantor Fitzgerald Overweight $21
Nov-08-21Initiated BTIG Research Buy $14
Nov-20-24 07:56AM
Nov-18-24 08:15AM
Nov-15-24 06:23AM
02:09AM
Nov-14-24 08:01AM
02:09AM Loading…
02:09AM
Nov-13-24 08:01AM
Nov-07-24 08:01AM
Nov-05-24 08:01AM
Oct-31-24 08:31AM
Oct-30-24 08:31AM
Oct-15-24 07:51AM
07:30AM
Oct-09-24 08:01AM
Oct-08-24 07:49AM
08:01AM Loading…
Oct-01-24 08:01AM
Sep-24-24 08:01AM
Sep-16-24 04:30PM
Sep-10-24 07:56AM
Sep-03-24 07:51AM
Aug-20-24 08:16AM
Aug-14-24 02:28AM
Aug-13-24 08:16AM
08:01AM
Aug-12-24 08:07AM
Aug-08-24 08:31AM
Aug-06-24 08:15AM
Aug-05-24 08:15AM
Jul-30-24 08:15AM
Jul-29-24 08:15AM
06:00AM Loading…
06:00AM
Jul-23-24 08:01AM
Jul-11-24 08:31AM
Jul-04-24 11:29AM
Jul-02-24 07:55AM
Jun-12-24 08:05AM
May-20-24 06:00AM
May-15-24 02:34AM
May-14-24 08:21AM
03:01AM
May-13-24 08:43PM
12:53PM
08:00AM
May-09-24 07:49AM
May-07-24 07:39AM
May-02-24 08:35AM
07:49AM
Apr-29-24 08:47AM
Apr-19-24 06:00AM
Apr-08-24 08:30AM
Mar-28-24 09:47AM
02:00AM
Mar-27-24 12:35PM
12:14AM
Mar-26-24 07:32PM
Mar-25-24 10:53PM
05:30PM
Mar-21-24 09:30AM
Mar-20-24 08:30AM
Mar-12-24 08:30AM
Feb-16-24 05:00PM
Feb-15-24 07:45AM
Feb-08-24 07:45AM
Dec-17-23 03:00PM
Dec-12-23 08:30AM
Dec-11-23 09:00AM
Dec-04-23 04:20PM
Nov-20-23 12:44PM
Nov-16-23 09:07AM
09:00AM
Nov-14-23 05:43PM
Nov-13-23 05:40PM
Nov-09-23 09:00AM
Nov-02-23 09:18AM
Nov-01-23 09:10AM
Oct-31-23 09:00AM
08:55AM
Sep-21-23 08:30AM
Sep-07-23 09:20AM
Sep-06-23 09:00AM
Aug-24-23 09:00AM
Aug-16-23 12:25AM
Aug-15-23 08:17PM
Aug-14-23 06:48PM
Jul-31-23 06:19PM
06:00PM
Jul-26-23 08:30AM
Jul-19-23 09:04AM
Jun-28-23 04:05PM
Jun-14-23 04:05PM
Jun-05-23 07:00AM
Jun-02-23 07:00AM
May-18-23 12:03PM
12:12AM
May-17-23 06:05AM
May-16-23 05:00PM
May-15-23 06:21PM
May-11-23 08:45AM
May-05-23 09:00AM
09:00AM
Lucid Diagnostics, Inc. is a commercial-stage medical diagnostics technology company. It focuses on patients with gastroesophageal reflux disease also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. The company was founded by Lishan Aklog on May 8, 2018 and is headquartered in New York, NY.